|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:chemicalFormula
|
C22H29FN3O9P
|
|
gptkbp:combinationTherapy
|
gptkb:peginterferon_alfa
ribavirin
ledipasvir
|
|
gptkbp:cost
|
high
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:drugClass
|
antiviral
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir)
27 hours (GS-331007 metabolite)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:FDAApproved
|
2013
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:sofosbuvir
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sovaldi
|
|
gptkbp:indication
|
gptkb:hepatitis_C
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketedAs
|
gptkb:Sovaldi
gptkb:sofosbuvir
|
|
gptkbp:mechanismOfAction
|
gptkb:NS5B_polymerase_inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2029 (US)
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
N (US)
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:priceControversy
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:successRate
|
high
|
|
gptkbp:target
|
gptkb:HCV
|
|
gptkbp:targetGene
|
NS5B polymerase
|
|
gptkbp:treatment
|
24 weeks
12 weeks
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:DB09223
gptkb:Gilead_Sciences
gptkb:Gilead
|
|
gptkbp:bfsLayer
|
5
|